JP2021517569A - シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム - Google Patents

シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム Download PDF

Info

Publication number
JP2021517569A
JP2021517569A JP2020548695A JP2020548695A JP2021517569A JP 2021517569 A JP2021517569 A JP 2021517569A JP 2020548695 A JP2020548695 A JP 2020548695A JP 2020548695 A JP2020548695 A JP 2020548695A JP 2021517569 A JP2021517569 A JP 2021517569A
Authority
JP
Japan
Prior art keywords
buprenorphine
silicone
treatment system
layer
containing layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2020548695A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517569A5 (cg-RX-API-DMAC7.html
Inventor
マルコ・エムゲンブロイフ
ガーブリエル・ヴァウアー
Original Assignee
エルテーエス ローマン テラピー−ジステーメ アーゲー
エルテーエス ローマン テラピー−ジステーメ アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エルテーエス ローマン テラピー−ジステーメ アーゲー, エルテーエス ローマン テラピー−ジステーメ アーゲー filed Critical エルテーエス ローマン テラピー−ジステーメ アーゲー
Publication of JP2021517569A publication Critical patent/JP2021517569A/ja
Publication of JP2021517569A5 publication Critical patent/JP2021517569A5/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020548695A 2018-03-13 2019-03-11 シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム Abandoned JP2021517569A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161418 2018-03-13
EP18161418.1 2018-03-13
PCT/EP2019/056010 WO2019175096A1 (en) 2018-03-13 2019-03-11 Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer

Publications (2)

Publication Number Publication Date
JP2021517569A true JP2021517569A (ja) 2021-07-26
JP2021517569A5 JP2021517569A5 (cg-RX-API-DMAC7.html) 2022-03-16

Family

ID=61628178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020548695A Abandoned JP2021517569A (ja) 2018-03-13 2019-03-11 シリコーンアクリルハイブリッドポリマーを含む、ブプレノルフィンの経皮投与のための経皮治療システム

Country Status (7)

Country Link
US (1) US20210000755A1 (cg-RX-API-DMAC7.html)
EP (1) EP3764995A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021517569A (cg-RX-API-DMAC7.html)
CN (1) CN111787913A (cg-RX-API-DMAC7.html)
BR (1) BR112020017484A2 (cg-RX-API-DMAC7.html)
CA (1) CA3092750A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019175096A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532418A (ja) * 2021-08-30 2024-09-05 エルテーエス ローマン テラピー-ジステーメ アーゲー グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101432698B1 (ko) 2006-06-06 2014-08-22 다우 코닝 코포레이션 실리콘 아크릴레이트 하이브리드 조성물
RU2544702C2 (ru) 2009-04-24 2015-03-20 Хенкель Корпорейшн Клеи на основе силикон-акрилового гибридного полимера
CA2815898C (en) * 2010-11-17 2018-12-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
JP2013139554A (ja) * 2011-11-29 2013-07-18 Dow Corning Corp シリコーンアクリレートハイブリッド組成物及び該組成物の製造方法
AU2013205080B2 (en) * 2012-12-12 2016-07-07 Lts Lohmann Therapie-Systeme Ag Transdermal Delivery System
WO2014195352A1 (en) * 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
KR102048682B1 (ko) 2015-02-09 2019-11-27 다우 실리콘즈 코포레이션 다중상 실리콘 아크릴 하이브리드 점탄성 조성물 및 이의 제조 방법
EP3349737A4 (en) * 2015-09-14 2019-05-15 Amneal Pharmaceuticals LLC SYSTEM FOR TRANSDERING
WO2018015424A1 (en) * 2016-07-22 2018-01-25 Lts Lohmann Therapie-Systeme Ag Control of adhesive domains

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024532418A (ja) * 2021-08-30 2024-09-05 エルテーエス ローマン テラピー-ジステーメ アーゲー グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム
JP7898514B2 (ja) 2021-08-30 2026-07-31 エルテーエス ローマン テラピー-ジステーメ アーゲー グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム

Also Published As

Publication number Publication date
WO2019175096A1 (en) 2019-09-19
CN111787913A (zh) 2020-10-16
US20210000755A1 (en) 2021-01-07
BR112020017484A2 (pt) 2020-12-22
CA3092750A1 (en) 2019-09-19
EP3764995A1 (en) 2021-01-20

Similar Documents

Publication Publication Date Title
JP7660162B2 (ja) シリコーンポリマーを含むグアンファシンの経皮投与のための経皮治療システム
US20220241215A1 (en) Transdermal therapeutic system comprising an active agent-containing layer comprising a silicone-containing polymer and a skin contact layer comprising a silicone gel adhesive
JP2021517576A (ja) ニコチン及びシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
JP2024532418A (ja) グアンファシン及びモノカルボン酸を含むグアンファシンの経皮投与のための経皮治療システム
EP3781138B1 (en) Transdermal therapeutic system for the transdermal administration of solifenacin
JP2020525546A (ja) スコポラミン及びシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム
JP2021517572A (ja) シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
JP2021515789A (ja) シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
JP7641279B2 (ja) フィンゴリモドの経皮投与のための経皮治療システム
US20210000755A1 (en) Transdermal therapeutic system for the transdermal administration of buprenorphine comprising a silicone acrylic hybrid polymer
JP2021515791A (ja) シリコーンアクリルハイブリッドポリマーを含む経皮治療システム
HK40043162A (en) Transdermal therapeutic system for the transdermal administration of solifenacin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220308

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20221028